Bavarian Nordic (OTCMKTS:BVNRY) Short Interest Up 50.0% in August

Bavarian Nordic (OTCMKTS:BVNRY) was the recipient of a significant growth in short interest in the month of August. As of August 14th, there was short interest totaling 633 shares, a growth of 50.0% from the July 30th total of 422 shares. Based on an average daily volume of 1,666 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the shares of the company are short sold.

Bavarian Nordic Trading Up 2.6%

Shares of OTCMKTS:BVNRY opened at $11.21 on Tuesday. Bavarian Nordic has a twelve month low of $8.67 and a twelve month high of $13.00. The company has a market cap of $2.67 billion, a PE ratio of 11.33 and a beta of 1.20. The company’s 50 day moving average is $9.53 and its 200 day moving average is $9.72.

Bavarian Nordic (OTCMKTS:BVNRY) last announced its quarterly earnings data on Friday, August 21st. The company reported $0.46 EPS for the quarter. The business had revenue of $316.47 million during the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 12.06%.

Bavarian Nordic Company Profile

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.